Comparative Pharmacology
Head-to-head clinical analysis: BUPIVACAINE HYDROCHLORIDE KIT versus CARBOCAINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BUPIVACAINE HYDROCHLORIDE KIT versus CARBOCAINE.
BUPIVACAINE HYDROCHLORIDE KIT vs CARBOCAINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Bupivacaine is an amide-type local anesthetic that blocks sodium channels in neuronal cell membranes, inhibiting the propagation of action potentials and thus producing local anesthesia and analgesia.
Mepivacaine, the active ingredient in Carbocaine, is an amide-type local anesthetic that blocks sodium ion channels in nerve cell membranes, thereby inhibiting the initiation and conduction of nerve impulses.
0.25% to 0.5% solution administered via epidural, peripheral nerve block, or local infiltration; maximum single dose 175 mg (without epinephrine) or 225 mg (with epinephrine 1:200,000); may repeat every 3-6 hours as needed, not to exceed 400 mg in 24 hours.
1% to 2% solution, 5-20 mL local infiltration or nerve block; maximum dose 400 mg (or 7 mg/kg) per 90-minute period.
None Documented
None Documented
Terminal elimination half-life is 2.7 to 3.5 hours in adults, prolonged in neonates (8-14 hours) and patients with hepatic impairment. Clinically, this supports intermittent dosing or continuous infusion monitoring.
2.0–3.5 hours in adults; prolonged in patients with hepatic impairment (up to 8–10 hours) or renal dysfunction.
Primarily hepatic metabolism (approx. 95%) to metabolites (e.g., pipecoloxylidine, desbutylbupivacaine); less than 5% excreted unchanged in urine. Biliary/fecal elimination accounts for a minor fraction. Renal clearance of unchanged drug is about 2-6%.
Renal excretion of unchanged drug and metabolites accounts for approximately 95% of elimination, with less than 5% excreted in feces via biliary elimination.
Category C
Category C
Local Anesthetic
Local Anesthetic